Noa Dagan

Noa Dagan, PhD

Director of Patient Data Core, DBMI Clalit Collaboration

Noa Dagan is a public health physician and medical informatics researcher. She holds an MD and an MPH from the Hebrew University and a Ph.D. in Computer Science from Ben-Gurion University. She completed her postdoc in the Department of Biomedical Informatics at Harvard Medical School.

Dr. Dagan heads the AI-driven Medicine Department at Clalit Innovation (Clalit is Israel's largest integrated healthcare organization, covering over 50% of the Israeli population). Her responsibilities include developing and implementing digital healthcare solutions to promote preventive, proactive, and personalized medicine. She leads the entire lifecycle of AI-driven interventions, from conception, through machine-learning modeling, to implementation in medical practice.

Dr. Dagan is also the co-director of the Digital Health Lab at the Software and Information Systems Engineering Department at Ben-Gurion University. Her research focuses on prediction models, algorithmic fairness, and causal inference based on real-world data.

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents.
Authors: Witberg G, Magen O, Hoss S, Talmor-Barkan Y, Richter I, Wiessman M, Aviv Y, Grinberg T, Shiyovich A, Schamroth-Pravda N, Auster O, Dagan N, Birk E, Balicer R, Kornowski R.
N Engl J Med
View full abstract on Pubmed
Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
Authors: Magen O, Waxman JG, Makov-Assif M, Vered R, Dicker D, HernĂ¡n MA, Lipsitch M, Reis BY, Balicer RD, Dagan N.
N Engl J Med
View full abstract on Pubmed
Comparing COVID-19-related hospitalization rates among individuals with infection-induced and vaccine-induced immunity in Israel.
Authors: Waxman JG, Makov-Assif M, Reis BY, Netzer D, Balicer RD, Dagan N, Barda N.
Nat Commun
View full abstract on Pubmed
Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older.
Authors: Auster O, Finkel U, Dagan N, Barda N, Laufer A, Balicer RD, Ben-Shachar S.
JAMA Netw Open
View full abstract on Pubmed
Validation of Heart Failure-Specific Risk Equations in 1.3 Million Israeli Adults and Usefulness of Combining Ambulatory and Hospitalization Data from a Large Integrated Health Care Organization.
Authors: Khan SS, Barda N, Greenland P, Dagan N, Lloyd-Jones DM, Balicer R, Rasmussen-Torvik LJ.
Am J Cardiol
View full abstract on Pubmed
Improving Cardiovascular Disease Prediction Using Automated Coronary Artery Calcium Scoring from Existing Chest CTs.
Authors: Barda N, Dagan N, Stemmer A, Yuval J, Bachmat E, Elnekave E, Balicer R.
J Digit Imaging
View full abstract on Pubmed
Indirect protection of children from SARS-CoV-2 infection through parental vaccination.
Authors: Hayek S, Shaham G, Ben-Shlomo Y, Kepten E, Dagan N, Nevo D, Lipsitch M, Reis BY, Balicer RD, Barda N.
View full abstract on Pubmed
Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting.
Authors: Mittelman M, Magen O, Barda N, Dagan N, Oster HS, Leader A, Balicer R.
View full abstract on Pubmed
Using population-level incidence of hepatitis C virus and immigration status for data-driven screening policies: a case study in Israel.
Authors: Leventer-Roberts M, Dagan N, Berent JM, Brufman I, Hoshen M, Braun M, Balicer RD, Feldman BS.
J Public Health (Oxf)
View full abstract on Pubmed
The role of observational studies based on secondary data in studying SARS-CoV-2 vaccines.
Authors: Barda N, Dagan N.
Clin Microbiol Infect
View full abstract on Pubmed